• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Minerva Neurosciences, Inc

    Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
    From Minerva Neurosciences, Inc
    Via GlobeNewswire
    Tickers NERV
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.